Free Trial
Stephen Willey

Stephen Willey Analyst Performance

Managing Director at Stifel Nicolaus

Stephen Willey is a stock analyst at Stifel Nicolaus focused in the medical sector, covering 26 publicly traded companies. Over the past year, Stephen Willey has issued 35 stock ratings, including buy and hold recommendations. While full access to Stephen Willey's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Stephen Willey's coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions.

Analyst Rankings, Coverage, and Performance Statistics

Average Return
00.00% 12-Month ROI
Success Rate
00.00% Profitable Ratings
Total Ratings
62 Last 10 Years
Buy Recommendations
71.43% 35 Buy Ratings
Companies Covered
26 Unique Companies

Ratings Distribution

RatingPercentageCount
Strong Buy0.0%0 ratings
Buy71.4%35 ratings
Hold28.6%14 ratings
Sell0.0%0 ratings

Out of 49 total stock ratings issued by Stephen Willey at Stifel Nicolaus, the majority (71.4%) have been Buy recommendations, followed by 28.6% Hold.

Exchange Coverage

ExchangePercentageCount
NASDAQ
100.0% of companies on NASDAQ
26 companies

Stephen Willey, an analyst at Stifel Nicolaus, currently covers 26 companies listed on , with the majority traded on NASDAQ.

Coverage Focus

Sector IconSectorPercentage
Medical
24 companies
92.3%
Manufacturing
2 companies
7.7%

Stephen Willey of Stifel Nicolaus specializes in stock coverage within the Medical sector, with additional focus on Manufacturing companies.

Coverage Industries

IndustryPercentage
MED - BIOMED/GENE
19 companies
73.1%
PHARMACEUTICAL PREPARATIONS
3 companies
11.5%
MED - DRUGS
1 company
3.8%
MED PRODUCTS
1 company
3.8%
BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES
1 company
3.8%
BIOTECHNOLOGY
1 company
3.8%

About Stephen Willey

Stephen Willey joined Stifel in 2010 with the acquisition of Thomas Weisel Partners LLC. Stephen is a Managing Director in the Healthcare sector, covering Biotechnology. Before joining Thomas Weisel Partners, Steven worked in research as a Research Scientist at ImClone Systems and as a Research Associate at Mount Sinai School of Medicine. Stephen received an undergraduate degree from University of New Hampshire, earned an MBA from New York University, and an M.S. from University of Rhode Island.

Stephen Willey's Ratings History at Stifel Nicolaus

Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.
Available with a MarketBeat All Access Subscription
12-Month ROIUpgrade to All Access to use the All ROI Filter
CompanyReport DateActionReport Date Price12-Month
Price Target
Rating12-Month
Price & ROI
Details
Incyte Corporation stock logo
INCY
Incyte
6/9/2026Set Price Target$102.93$123.00
Compass Therapeutics, Inc. stock logo
CMPX
Compass Therapeutics
6/1/2026Set Price Target$2.25$6.00
Exelixis, Inc. stock logo
EXEL
Exelixis
5/6/2026Boost Price Target$47.52$47.00Hold
Celcuity, Inc. stock logo
CELC
Celcuity
5/4/2026Set Price Target$125.65$150.00
Incyte Corporation stock logo
INCY
Incyte
4/29/2026Boost Price Target$97.74$123.00Buy
Celcuity, Inc. stock logo
CELC
Celcuity
3/26/2026Boost Price Target$113.25$125.00Buy
Insmed, Inc. stock logo
INSM
Insmed
3/24/2026Boost Price Target$139.20$208.00Buy
Abeona Therapeutics Inc. stock logo
ABEO
Abeona Therapeutics
3/17/2026Set Price Target$4.76$17.00
Zymeworks Inc. stock logo
ZYME
Zymeworks
3/3/2026Boost Price Target$24.10$47.00Buy
Syndax Pharmaceuticals, Inc. stock logo
SNDX
Syndax Pharmaceuticals
2/27/2026Set Price Target$21.71$45.00
Crescent Biopharma, Inc. stock logo
CBIO
Crescent Biopharma
2/26/2026Set Price Target$12.35$29.00
Arcellx, Inc. stock logo
ACLX
Arcellx
2/23/2026Reiterated Rating$113.75$115.00Hold
Disc Medicine, Inc. stock logo
IRON
Disc Medicine
2/17/2026Lower Price Target$63.10$110.00Buy
Incyte Corporation stock logo
INCY
Incyte
2/11/2026Boost Price Target$100.05$120.00Buy
Exelixis, Inc. stock logo
EXEL
Exelixis
2/11/2026Boost Price Target$42.36$44.00Hold
Nurix Therapeutics, Inc. stock logo
NRIX
Nurix Therapeutics
1/29/2026Boost Price Target$18.58$35.00Buy
Incyte Corporation stock logo
INCY
Incyte
1/5/2026Set Price Target$101.79$119.00
Crescent Biopharma, Inc. stock logo
CBIO
Crescent Biopharma
12/4/2025Set Price Target$12.99$32.00
Janux Therapeutics, Inc. stock logo
JANX
Janux Therapeutics
12/2/2025Lower Price Target$33.99$38.00Buy
Zymeworks Inc. stock logo
ZYME
Zymeworks
11/19/2025Boost Price Target$22.99$40.00Buy
Celcuity, Inc. stock logo
CELC
Celcuity
11/13/2025Boost Price Target$87.09$115.00Buy
Nkarta, Inc. stock logo
NKTX
Nkarta
11/11/2025Lower Price Target$1.99$11.00Buy
X4 Pharmaceuticals, Inc. stock logo
XFOR
X4 Pharmaceuticals
11/5/2025Set Price Target$3.60$7.50
Exelixis, Inc. stock logo
EXEL
Exelixis
11/5/2025Set Price Target$39.82$43.00
Disc Medicine, Inc. stock logo
IRON
Disc Medicine
11/3/2025Initiated Coverage$86.22$125.00Buy
Arcellx, Inc. stock logo
ACLX
Arcellx
10/16/2025Set Price Target$92.37$129.00Buy
Incyte Corporation stock logo
INCY
Incyte
9/22/2025Boost Price Target$85.39$115.00Buy
X4 Pharmaceuticals, Inc. stock logo
XFOR
X4 Pharmaceuticals
8/29/2025Lower Price Target$4.12$9.00Buy
Nkarta, Inc. stock logo
NKTX
Nkarta
8/14/2025Lower Price Target$2.21$12.00Buy
Insmed, Inc. stock logo
INSM
Insmed
8/14/2025Boost Price Target$125.13$145.00Buy
AbCellera Biologics Inc. stock logo
ABCL
AbCellera Biologics
8/8/2025Lower Price Target$4.13$7.00Buy
Exelixis, Inc. stock logo
EXEL
Exelixis
7/29/2025Boost Price Target$44.39$41.00Hold
Celcuity, Inc. stock logo
CELC
Celcuity
7/1/2025Initiated Coverage$13.35$30.00Buy
Crescent Biopharma, Inc. stock logo
CBIO
Crescent Biopharma
6/25/2025Initiated Coverage$15.06$28.00Buy
Incyte Corporation stock logo
INCY
Incyte
6/16/2025Upgrade$67.75$107.00Buy
MacroGenics, Inc. stock logo
MGNX
MacroGenics
5/14/2025Lower Price Target$1.53$5.00Hold
Exelixis, Inc. stock logo
EXEL
Exelixis
5/14/2025Boost Price Target$43.58$38.00Hold
Bolt Biotherapeutics, Inc. stock logo
BOLT
Bolt Biotherapeutics
5/13/2025Lower Price Target$7.00$20.00Hold
Nurix Therapeutics, Inc. stock logo
NRIX
Nurix Therapeutics
4/9/2025Lower Price Target$8.88$35.00Buy
Nkarta, Inc. stock logo
NKTX
Nkarta
3/27/2025Lower Price Target$1.37$14.00Buy
The chokepoint supplier behind SpaceX's $1.75 trillion empire (Ad)

When Musk laughed and said 'you need transformers to run transformers,' it wasn't a joke - it was a confession. The world's largest supercomputer requires power equipment that takes 120 weeks to build, and Musk built Colossus in just 122 days. One small American company is positioned to close that gap faster than anyone else, yet Wall Street still prices it like an afterthought. Dylan Jovine has the full story and the ticker.tc pixel

See the stock Musk's own words pointed to right here
Bolt Biotherapeutics, Inc. stock logo
BOLT
Bolt Biotherapeutics
3/25/2025Lower Price Target$8.75$25.00Hold
Vor Biopharma Inc. stock logo
VOR
Vor Biopharma
3/21/2025Lower Price Target$17.04$100.00Buy
AbCellera Biologics Inc. stock logo
ABCL
AbCellera Biologics
2/28/2025Lower Price Target$2.93$10.00Buy
Geron Corporation stock logo
GERN
Geron
2/27/2025Lower Price Target$1.62$4.00Buy
Insmed, Inc. stock logo
INSM
Insmed
2/21/2025Lower Price Target$84.49$96.00Buy
Exelixis, Inc. stock logo
EXEL
Exelixis
2/12/2025Boost Price Target$35.11$36.00Hold
Insmed, Inc. stock logo
INSM
Insmed
2/11/2025Boost Price Target$78.94$97.00Buy
Incyte Corporation stock logo
INCY
Incyte
2/10/2025Boost Price Target$68.30$77.00Hold
Nurix Therapeutics, Inc. stock logo
NRIX
Nurix Therapeutics
1/29/2025Boost Price Target$19.56$36.00Buy
IGM Biosciences, Inc. stock logo
IGMS
IGM Biosciences
1/10/2025Downgrade$6.20$2.50Hold